Important data from #ESMO2026 in #mCRPC:
🧬 56% of HRR alterations detected by liquid biopsy were predicted to originate from clonal hematopoiesis (CH).
⚠️ Patients with CH-only HRR alterations did not appear to benefit from PARPi monotherapy.
Distinguishing CH from tumor-derived mutations is critical for treatment selection. #ProstateCancer @EAntonarakis @urotoday @PCF_Science @OncoAlert
346 views · 10 likes · 3 reposts · 0 replies
Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: Implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)
https://esmocongress.esmo.orgPlasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.orgSource: Yu-Wei Chen, MD, MS · x.com